Now you can get access to the latest and highest-quality analysis of recent Wall Street buying and selling ideas with just one subscription to Beyond the Wall Investing ! There is a free trial and a special discount of 10% for you. Join us today!My first-ever article on UnitedHealth ( UNH ) came out in mid-May 2025 , right after the stock's heavy drop on pulling its guidance and replacing the previousDaniel Sereda is chief investment analyst at a family office whose investments span continents and diverse a ...

Core Insights - UnitedHealth Group (UNH) reported Q4 2025 earnings that slightly missed revenue expectations at $113.2 billion, compared to the anticipated $113.7 billion, while meeting EPS forecasts at $2.11. The company faced significant challenges with a nearly flat 0.09% increase in the Medicare Advantage rate for 2027, which was well below the expected 4-6% increase, and a surge in the medical care ratio to 88.9%, up 340 basis points year-over-year, leading to a 19% drop in stock price [2][4][12]. Financial Performance - Full-year 2025 revenue reached $447.6 billion, marking a 12% increase, but 2026 revenue guidance is projected to decline to over $439 billion, a decrease of 2% [11]. - Q4 2025 adjusted EPS was $2.11, down 65% from $5.98 in Q4 2024, with full-year 2025 adjusted EPS at $16.35 and 2026 adjusted EPS guidance exceeding $17.75, indicating an 8.6% growth [12]. - The operating margin for 2025 was 2.7%, with projections to improve to 5.5% in 2026 [12]. - Cash flow from operations was robust at $19.7 billion, which is 1.5 times net income, despite incurring a $1.6 billion restructuring charge and a $799 million revenue loss due to a cyberattack [12]. Medicare Advantage Challenges - The adjusted medical care ratio of 88.9% indicates that UNH is spending $0.89 of every premium dollar on medical claims, up from 85.5% in 2024, driven by a 7.5% increase in medical expenses for Medicare Advantage that outpaced pricing [4][5]. - The proposed 2027 rate increase is virtually zero, compounded by a new CMS policy that removes 1.53 percentage points from diagnoses not associated with actual medical visits, which will continue to squeeze margins [5][14]. Market Position and Valuation - UNH is experiencing its first annual revenue decline since 1989, with management planning to eliminate unprofitable Medicare Advantage members, anticipating a loss of about 1 million members in 2026 [7]. - At a current price of approximately $285, UNH trades at about 16 times the estimated EPS of $17.75 for 2026, which is below its historical trading range of 18-22 times forward earnings, suggesting a potential upside of 40% based on analyst consensus with a strong buy rating and an average price target of around $396 [9][12]. Regulatory and Structural Issues - There is ongoing regulatory uncertainty regarding the preliminary 0.09% rate, with final rates to be announced in April, alongside a DOJ investigation into Medicare billing practices and structural margin compression in Medicare Advantage [13][15]. - The 2027 rate proposal, if finalized, could fundamentally alter the economics of Medicare Advantage, posing significant short-term challenges for UNH despite its historical ability to adapt and achieve over 15% annual returns in the past decade [15].

Core Insights - Several U.S. politicians sold UnitedHealth stock shortly before a significant market crash on January 27, 2026, raising concerns about the timing of these transactions [1][6][10] Group 1: Stock Performance and Market Impact - UnitedHealth experienced a dramatic loss of approximately 19% in a single trading session, closing at $282.70, which contributed to a nearly 50% decline in its stock value over the past year [2][9] - The company's market capitalization was significantly affected, erasing tens of billions of dollars and dragging down the Dow Jones Industrial Average [1] Group 2: Revenue Guidance and Financial Concerns - UnitedHealth's revenue guidance for 2026 was projected at about $439 billion, falling short of Wall Street estimates of $454 to $456 billion, which contributed to the stock's decline [9] - Rising medical costs and weaker earnings, along with proposed Medicare Advantage payment increases of only 0.09% for 2027, further exacerbated the situation [9] Group 3: Congressional Stock Transactions - Notable transactions included Rep. Kevin Hern selling UnitedHealth shares valued between $250,001 and $500,000 on December 23, 2025, just weeks before the stock's plunge [3][6] - Rep. Julie Johnson sold shares twice in November and December 2025, with each sale ranging from $1,001 to $15,000, occurring while the stock was still perceived as a defensive play [7] - Rep. Gilbert Cisneros sold shares on November 12, 2025, and later purchased shares on December 19, 2025, shortly before the company's outlook worsened [8]

Core Viewpoint - UnitedHealth Group (NYSE:UNH) is a leading healthcare company in the U.S., providing a wide range of health benefits and services, and competes with major players like Anthem and Cigna [1] Group 1: Stock Performance - On January 27, 2026, UNH's stock experienced a significant downturn, plummeting by 19.8% to $281.96, marking its worst single-day percentage loss since April [2] - The stock's decline amounted to $70.08, or approximately 19.93%, bringing its price to $281.56, with a trading day low of $280.40 and a high of $299.50 [3] - The trading volume for the day reached 56.14 million shares, indicating heightened investor activity amid the stock's sharp decline [4] Group 2: Market Outlook - Piper Sandler set a price target of $396 for UNH, suggesting a potential price increase of approximately 40.56% from its current trading price of $281.73 [2] - Despite the downturn, UNH's market capitalization remains robust at approximately $255.05 billion, highlighting its significant presence in the healthcare industry [5] - Over the past year, UNH has seen a high of $606.36 and a low of $234.60, showcasing its price fluctuations in the market [4]

Market Performance - The Nasdaq and S&P 500 opened positively, with the S&P 500 reaching a new all-time closing high of 6978, up by +0.41% [1] - The Dow Jones Industrial Average fell by -408.99 points, or -0.83%, primarily due to a -19% loss in UnitedHealth (UNH) following mixed Q4 results [1] Economic Reports - The Case-Shiller Home Prices for November showed a slight improvement, with a +1.4% increase, and house prices rose +0.6% month over month and +1.9% year over year, although these figures lag behind the +2.7% inflation rate [2] - Consumer Confidence for January dropped significantly to 84.5, down nearly 10 points from a revised December figure of 94.2, indicating levels typically associated with an impending recession [4][5] Company Earnings - Texas Instruments (TXN) reported Q4 earnings of $1.27 per share, missing estimates by 3 cents, with revenues of $4.42 billion also falling short of expectations [6] - F5 (FFIV) exceeded earnings expectations with $4.45 per share on revenues of $822 million, leading to a +13% increase in after-hours trading [7] - Seagate Technologies (STX) reported fiscal Q2 earnings of $3.19 per share on revenues of $2.83 billion, surpassing estimates, although shares fell -1.3% after a significant year-to-date increase of nearly +35% [9]

Market Overview - The S&P 500 closed at a record high, up about 28 points or 0.4%, while the Nasdaq increased by approximately 0.9%. The Dow Jones Industrial Average saw a decline of about 0.8% [7] - Nine sectors in the S&P 500 were in the green, with big tech stocks performing well, up by about 1.4%. The healthcare sector, however, faced a decline of about 1.7% [8] Texas Instruments Earnings - Texas Instruments reported a fourth-quarter EPS of $1.27, missing the Street's estimate of $1.30, and showing a year-over-year decline [10] - Revenue grew by about 10% to $4.42 billion, in line with estimates, with 14% growth in the analog business and 8% growth in embedded processing [11] - The company invested $3.9 billion in R&D and $4.6 billion in CapEx over the past 12 months, returning $6.5 billion to owners [13] Seagate Earnings - Seagate's second-quarter revenue was reported at $3 billion, slightly above estimates of $2.75 billion, with adjusted EPS of $3.11, beating the estimate of $2.83 [20] - Despite positive revenue and EPS results, the stock declined by 3.2% in after-hours trading, likely due to forecast concerns [21] Healthcare Sector Impact - Medicare Advantage payment rates are set to rise by only 0.09% next year, surprising the market and negatively impacting healthcare stocks [9] - UnitedHealthcare, CVS, and Humana saw significant declines, with UnitedHealth down 19.6%, CVS down 14%, and Humana down over 21% [22] Other Notable Stocks - Corning's stock rose by about 16% after announcing a multiyear agreement worth up to $6 billion with Meta for optical fiber and connectivity solutions [17] - HCA Healthcare shares increased by about 7% after better-than-expected guidance eased investor concerns regarding expiring Affordable Care Act subsidies [19] - JetBlue reported a wider loss than expected, leading to a 6.9% decline in its shares [23] - Pinterest announced layoffs of less than 15% of its workforce, resulting in a 9.6% drop in its stock [24]

Core Insights - UnitedHealth Group's stock decline significantly impacted the Dow Jones Industrial Average, contributing to a 422-point drop, which accounted for the entire 409-point decline of the index on that day [1][1][1] Company Performance - UnitedHealth's shares fell nearly 20%, losing $69 each, after disappointing earnings were reported [1][1] - The company faced a dual setback as Medicare administrators announced minimal increases in payments to private Medicare Advantage plans, and UnitedHealth forecasted a decline in total revenue for the year due to operational cutbacks [1][1] Market Impact - The Dow Jones Industrial Average fell by 0.8%, while the S&P 500 and Nasdaq saw gains of 0.4% and 0.9%, respectively, indicating a divergence in performance among major indexes [1][1] - UnitedHealth Group, being one of the most expensive stocks in the Dow, had a significant influence on the index's performance due to its price-weighted methodology [1][1][1] Related Stocks - Other influential stocks in the Dow, such as Goldman Sachs, Home Depot, and American Express, also experienced declines, but UnitedHealth's drop was the primary driver of the index's negative performance [1][1]

Core Insights - UnitedHealth Group's Optum health services is undergoing a strategic turnaround, which includes exiting certain markets and terminating contracts with misaligned medical care providers [2][4] - The company aims to enhance its value-based care model to ensure patients receive appropriate care at the right time and cost [4][5] Financial Performance - UnitedHealth's fourth quarter net income fell to $10 million, a significant drop from $5.5 billion year-over-year, while full-year net income decreased to $12 billion from $14.4 billion [6] - Optum's revenues increased by 8% in Q4 to $70.3 billion and by 7% for the year to $270.6 billion, compared to $253 billion in 2024 [6] - However, Optum Health's full-year revenues declined by 3% to $102 billion, with adjusted earnings from operations dropping to $2.3 billion from $7.9 billion in 2024 [7] Strategic Focus - Optum plans to achieve approximately 9% operating earnings growth in 2026 by concentrating on integrated value-based care [8] - The company will reduce its affiliated network by nearly 20% to better align physicians and services [8] - Optum will eliminate unaligned PPO contracts and reposition certain markets to enhance operational efficiency [8] Technological Advancements - The company is pushing its medical care providers to adopt advanced technology and artificial intelligence to improve care delivery [8] - Nearly 100% of employed provider groups are now using one of three strategic electronic medical records systems, down from 18, facilitating better data management and workflow [9]

Core Viewpoint - UnitedHealth Group shares experienced a significant decline due to lower-than-expected Medicare Advantage payment increases, leading to a selloff in managed care stocks Group 1: Medicare Advantage Payment Changes - Federal regulators announced that Medicare Advantage rates would rise by only 0.09% in 2027, significantly below the anticipated increases of up to 6% [1] - This announcement triggered a broad selloff across managed care stocks, impacting investor sentiment negatively [1] Group 2: Financial Performance - UnitedHealth reported fourth-quarter adjusted earnings of $2.11 per share, slightly exceeding analyst estimates of $2.10 [2] - Despite the earnings beat, the company faced concerns due to a rising medical care ratio, which increased to 88.9% from 85.5%, indicating lower Medicare funding and higher utilization [2] Group 3: Future Earnings Guidance - The company forecasted 2026 adjusted earnings per share of more than $17.75, marginally above the analyst consensus of $17.74 [3] - The modest guidance did not alleviate concerns regarding the impact of restrained Medicare reimbursement growth on earnings [3] - UnitedHealth shares had already declined approximately 35% in 2025, reflecting investor caution regarding healthcare cost inflation and ongoing regulatory pressures in the managed care sector [3]

Core Viewpoint - UnitedHealth Group Incorporated (UNH) is under close scrutiny from investors, hedge funds, and analysts, indicating its significance in the market [1]. Company Analysis - The stock of UnitedHealth Group has been covered multiple times by analysts, reflecting ongoing interest and analysis of its performance [1]. - The company has a beneficial long position in its shares, suggesting confidence in its future performance [1]. Investment Perspective - The focus on identifying great businesses at reasonable prices indicates a long-term investment strategy, which is relevant for potential investors considering UNH [1].